Cited by

• Ovarian cancer in BRCA1 and BRCA2 gene mutation carriers: analysis of prognostic factors and survival.

  Biglia N, Sgandurra P, Bounous VE, Maggiorotto F, Piva E, Pivetta E, Ponzone R, Pasini B. Biglia N, et al. Ecancermedicalscience. 2016 May 3;10:639. doi: 10.3332/ecancer.2016.639. eCollection 2016. Ecancermedicalscience. 2016. PMID: 27350785 Free PMC article.
• Expression and Function of Eicosanoid-Producing Cytochrome P450 Enzymes in Solid Tumors.

  Evangelista EA, Cho CW, Aliwarga T, Totah RA. Evangelista EA, et al. Front Pharmacol. 2020 Jun 9;11:828. doi: 10.3389/fphar.2020.00828. eCollection 2020. Front Pharmacol. 2020. PMID: 32581794 Free PMC article. Review.
• Improved survival in non-Ashkenazi Jewish ovarian cancer patients with BRCA1 and BRCA2 gene mutations.

  Lacour RA, Westin SN, Meyer LA, Wingo SN, Schorge JO, Brooks R, Mutch D, Molina A, Sutphen R, Barnes M, Elder J, Teoh D, Powell CB, Choubey V, Blank S, Macdonald HR, Brady MF, Urbauer DL, Bodurka D, Gershenson DM, Lu KH. Lacour RA, et al. Gynecol Oncol. 2011 May 1;121(2):358-63. doi: 10.1016/j.ygyno.2010.12.354. Epub 2011 Jan 28. Gynecol Oncol. 2011. PMID: 21276604 Free PMC article.
• GEICO (Spanish Group for Investigation on Ovarian Cancer) treatment guidelines in ovarian cancer 2012.

  González Martín A, Redondo A, Jurado M, De Juan A, Romero I, Bover I, Del Campo JM, Cervantes A, García Y, López-Guerrero JA, Mendiola C, Palacios J, Rubio MJ, Poveda Velasco A. González Martín A, et al. Clin Transl Oncol. 2013 Jul;15(7):509-25. doi: 10.1007/s12094-012-0995-8. Epub 2013 Mar 7. Clin Transl Oncol. 2013. PMID: 23468275 Free PMC article.
• Effectiveness and safety of poly (ADP-ribose) polymerase inhibitors in cancer therapy: A systematic review and meta-analysis.

  Bao Z, Cao C, Geng X, Tian B, Wu Y, Zhang C, Chen Z, Li W, Shen H, Ying S. Bao Z, et al. Oncotarget. 2016 Feb 16;7(7):7629-39. doi: 10.18632/oncotarget.5367. Oncotarget. 2016. PMID: 26399274 Free PMC article.